Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All

Johnson & Johnson, Viacyte Testing Possible Diabetes Cure

February 4, 2016 10:45 am | by Linda A. Johnson, AP Business Writer | News | Comments

Johnson & Johnson, continuing its long quest for a Type 1 diabetes cure, is joining forces with biotech company ViaCyte to speed development of the first stem cell treatment that could fix the life-threatening hormonal disorder. Read more...


Diabetes Discovery Could Lead to More Effective Drugs

February 4, 2016 8:33 am | by University of Melbourne | News | Comments

The formation of type 2 diabetes is directly related to how our muscles convert sugar, a landmark new study has found. Researchers at the University of Melbourne's Medical School at the Austin Hospital have used elegant gene splicing technology to prove this popular theory about the biological cause of Type 2 diabetes. Read more...


New Insights into Function of Main Class of Drug Targets

February 4, 2016 8:32 am | by University of Basel | News | Comments

A wide variety of drugs such as beta-blockers against high blood pressure or drugs against allergies, cancer, Parkinson's disease, HIV and others bind to cell surface proteins which belong to the family of G protein coupled receptors. Read more...


GSK Posts Loss as it Integrates New Businesses

February 4, 2016 8:32 am | by Danica Kirka, The Associated Press | News | Comments

Drugmakers like GSK have been trying to focus on strengths amid competition from generic drugmakers. Read more...


EU Approves AstraZeneca's Lung Cancer Drug

February 4, 2016 8:31 am | News | Comments

Mutations in the EGFR receptor can lead to uncontrolled cell growth and tumor formation. Read more...


Aspirin Could Reduce Risk of Staph Blood Infections

February 4, 2016 8:30 am | by Ryan Bushey, Associate Editor | News | Comments

Aspirin has been previously linked to lowering risk of various heart conditions. Read more...


BMJ Investigation Casts Doubt on Validity of Rivaroxaban Trial

February 4, 2016 8:30 am | by Stephanie Guzowski, Editor | News | Comments

New questions have been raised about the validity and reliability of data in the ROCKET-AF trial, which serves as the backbone for the approval of rivaroxaban (Xarelto), according to an investigation published Wednesday by The BMJ. Rivaroxaban is a blockbuster drug for stroke prevention in atrial fibrillation (AF) that gained approval from both U.S. and European regulators. Read more...


Several Blockbuster Drugs to Arrive This Year as Prescription Prices Rise

February 3, 2016 10:43 am | by Ryan Bushey, Associate Editor | Articles | Comments

Liver disease and HIV therapies are cited as the leading treatments. Read more...


Case of Sexually Transmitted Zika is Confirmed in Texas

February 3, 2016 9:52 am | by Jamie Stengle, Associated Press | News | Comments

Health officials say a person in Texas has become infected with the Zika virus through sex, in the first case of the illness being transmitted within the United States amid the current outbreak in Latin America. Read more...


New Drug Target for Rett Syndrome

February 3, 2016 9:46 am | by Harvard University | News | Comments

Harvard Stem Cell Institute (HSCI) researchers have identified a faulty signaling pathway that, when corrected, in mice ameliorates the symptoms of Rett syndrome, a devastating neurological condition. Read more...


Merck Beats 4Q Profit Forecast, Misses Street View on Sales

February 3, 2016 9:39 am | by Linda A. Johnson, AP Business Writer | News | Comments

Merck & Co. posted an 87 percent drop in fourth-quarter profit compared with last year when the drugmaker had a huge gain from the sale of consumer health business. It beat Wall Street profit forecasts, but came up short of revenue. Read more...


Inhibiting Apolipoprotein C-III Production to Reduce Triglyceride Levels in Patients With FCS

February 3, 2016 8:55 am | by Rosanne M. Crooke, Ph.D., Ionis Pharmaceuticals | Articles | Comments

In recent years research has presented important new findings regarding the mechanism of action of familial chylomicronemia syndrome (FCS), a rare genetic disease that affects production or functionality of lipoprotein lipase (LPL), an enzyme necessary for the metabolism of triglycerides (TG). Read more...


Documents Detail Price Hike Decisions by Turing, Valeant

February 3, 2016 8:36 am | by Matthew Perrone and Tom Murphy, AP Business Writers | News | Comments

Federal lawmakers have released excerpts from thousands of documents detailing how two drugmakers hiked prices to squeeze more money from some life-saving medicines. Read more...


French Caribbean Facing Zika Epidemic, Taking Extra Measures

February 3, 2016 8:33 am | by The Associated Press | News | Comments

France's health minister said two French regions in the Caribbean are facing an epidemic of the Zika virus. Read more...


New Target for Fatty Liver Disease Treatment Discovered

February 3, 2016 8:27 am | by CNIC | News | Comments

Steatosis, the excessive accumulation of fat in the liver, is one of the most common diseases in developed societies. Read more...



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.